Search Result

Results for "

α-Amylase Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (36) Apoptosis (1) Bacterial (1) Cholinesterase (ChE) (1) COX (1) Dipeptidyl Peptidase (2) Endogenous Metabolite (1) Fatty Acid Synthase (FASN) (1) Fungal (1) Glucosidase (29) GLUT (2) HDAC (1) NF-κB (2) P-glycoprotein (1) Phosphatase (1) Tyrosinase (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (1) Endocrinology (2) Infection (1) Inflammation/Immunology (5) Metabolic Disease (44) Neurological Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135530

Chinese gallotannin	Amylases	Metabolic Disease
Chinese gallotannin is a non-specific promiscuous *α-amylase* inhibitor with a K_i of 0.82 μg/mL for human salivary α-amylase. Chinese gallotannin can be used for the research of diabetes .

HY-146752

α-Amylase-IN-1	Others	Others
α-Amylase-IN-1 is a potent *α-amylase* inhibitor with an IC_{50 of 4.46 μM .}

HY-162673

α-Amylase/α-Glucosidase-IN-16	Amylases Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-16 (compound 15) is a potent dual inhibitor of *α-amylase* and α-Glucosidase with IC₅₀ values of 0.8 and 1.2 μM, respectively. α-Amylase/α-Glucosidase-IN-16 can be used in the study of diabetes mellitus (DM) .

HY-N12263

3,5,6,7,8,4'-Hexamethoxyflavone	Amylases	Metabolic Disease
3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of *α-Amylase* with the inhibitory activity of 28.3% at 500 μM .

HY-N11844

Quercetin 3-(6″-caffeoylsophoroside)	Amylases	Metabolic Disease
Quercetin 3-(6″-caffeoylsophoroside) is an orally active *α-amylase* inhibitor, with an IC₅₀ of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .

HY-157537

α-Amylase-IN-5	Amylases	Metabolic Disease
α-Amylase-IN-5 (compound 3a) is a *α-amylase* inhibitor, with an IC₅₀ of 18.8 mM .

HY-146225

α-Amylase/α-Glucosidase-IN-2	Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent *α-amylase* and α-glucosidase dual inhibitor with IC₅₀ values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .

HY-161782

α-Amylase-IN-7	Amylases	Metabolic Disease
α-Amylase-IN-7 (Compound 6e) is an inhibitor for *α-Amylase* with an IC₅₀ of 40 μM. α-Amylase-IN-7 exhibits potential as an antidiabetic agent .

HY-161944

α-Amylase-IN-8	Amylases	Metabolic Disease
α-Amylase-IN-8 (compound 44) is an *α-amylase* inhibitor (IC₅₀=58.1 μM). α-Amylase-IN-8 can be used in the research of type 2 diabetes .

HY-162634

α-Amylase/α-Glucosidase-IN-15	Amylases Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-15 (compound 6C) is an oral bioactive inhibitor of α-Glucosidase and *α-amylase, with the IC₅₀*s of 21 μM and 61 μM, respectively .

HY-149008

α-Amylase-IN-3	Amylases	Metabolic Disease Cancer
α-Amylase-IN-3 (Compound 4) is a none-competitive type of *α-Amylase* inhibitor with an IC₅₀ value of 18.04 μM, which also has radical scavenging activities (DPPH and ABTS) with IC₅₀ values of 16.04 μM (DPPH) and 16.99 μM (ABTS), respectively. α-Amylase-IN-3 has good protein–ligand interactions profile against α-Amylase. α-Amylase-IN-3 may have pharmacological activities such as anti-oxidative, anti-inflammatory inhibitory, which is helpful for the development of diabetes and oxidative stress associated disease .

HY-147711

α-Amylase/α-Glucosidase-IN-1	Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent *α-amylase/α-glucosidase* inhibitor with IC₅₀s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .

HY-161355

α-Amylase/α-Glucosidase-IN-9	Amylases Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both *α-amylase* (IC₅₀ = 16.4 μM) and α-glucosidase (IC₅₀ = 31.6 μM) enzymes .

HY-162635

α-Amylase/α-Glucosidase-IN-14	Amylases Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-14 (compound 6E) is an oral bioactive inhibitor of *α-amylase* and α-glucosidase, with the IC₅₀s of 45.53 μM and 27.73 μM, respectively .

HY-149557

α-Amylase/α-Glucosidase-IN-5	Glucosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-155241

α-Amylase/α-Glucosidase-IN-4	Glucosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-156380

α-Amylase/α-Glucosidase-IN-6	Amylases Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of *α-amylase* and α-glucosidase, with IC₅₀s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .

HY-132179

Fucoidan 2 Publications Verification	Glucosidase	Cardiovascular Disease Metabolic Disease Cancer
Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities .

HY-162390

α-Amylase/α-Glucosidase-IN-11	Amylases Glucosidase	Endocrinology
α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits *α-amylase* (IC₅₀ = 30.39 μM) and α-glucosidase (IC₅₀ = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier .

HY-162169

α-Amylase/α-Glucosidase-IN-8	Amylases Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of *α-amylase* and α-glucosidase, with IC₅₀s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC₅₀ = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .

HY-162036

α-Amylase/α-Glucosidase-IN-7	Glucosidase Amylases Cholinesterase (ChE)	Neurological Disease Metabolic Disease
α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive α-glucosidase and *α-amylase* enzyme inhibitor with IC₅₀ values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC₅₀ values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research .

HY-163439

α-Amylase/α-Glucosidase-IN-12	Amylases Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC₅₀ of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research .

HY-N1425

Tiliroside	Others	Metabolic Disease
Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of *α-amylase* with a K_i value of 84.2? μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .

HY-N10413

Diphlorethohydroxycarmalol	Glucosidase	Metabolic Disease
Diphlorethohydroxycarmalol, a kind of phlorotannin, is an orally active α-glucosidase and *α-amylase* inhibitor with IC₅₀s of 0.16 mM and 0.53 mM, respectively. Diphlorethohydroxycarmalol has anti-diabetic activities .

HY-W727627

5-O-Coumaroylquinic acid	Amylases	Metabolic Disease
5-O-Coumaroylquinic acid is a potent, reversible, non-competitive *α-amylase* inhibitor with an IC₅₀ value of 69.39 μM. 5-O-Coumaroylquinic acid can be used in diabetes research .

HY-162373

α-Amylase/α-Glucosidase-IN-10	Amylases Glucosidase P-glycoprotein	Metabolic Disease
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC₅₀: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .

HY-143268

HPA-IN-1	Amylases Glucosidase	Metabolic Disease
HPA-IN-1 (Compound 1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC₅₀ values of 12.0 μM and 410.4 μM against HPA and α-glucosidase, respectively .

HY-N7729

Sekikaic acid	Amylases Glucosidase	Metabolic Disease
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .

HY-W005598

2-Hydroxyquinoline	Glucosidase	Metabolic Disease
2-Hydroxyquinoline is a potent α-glucosidase inhibitor with IC₅₀ values of 64.4, 130.5 µg/mL for α-glucosidase and α-amylase, respectively. 2-Hydroxyquinoline has the potential for the research of diabetes .

HY-143269

HPA-IN-2	Amylases Glucosidase	Metabolic Disease
HPA-IN-2 (Compound 2a-1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC₅₀ values of 8.2 μM and 450.7 μM against HPA and α-glucosidase, respectively .

HY-N0668

Rubusoside 2 Publications Verification	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .

HY-N1425R

Tiliroside (Standard)	Others	Metabolic Disease
Tiliroside (Standard) is the analytical standard of Tiliroside. This product is intended for research and analytical applications. Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of *α-amylase* with a K_i value of 84.2? μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .

HY-N0668R

Rubusoside (Standard)	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits *NF-κB and α-amylase* (α-amylase) .**

HY-149313

α‑Amylase-IN-1	Amylases	Metabolic Disease
α Amylase-IN-1 (Compound 11) is an *α-Amylase* inhibitor with an IC₅₀ value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC₅₀ value of 53.49 μM for scavenging DPPH free radicals. IC₅₀ can be used in the study of diabetes and oxidative stress-related diseases.

HY-161429

Antidiabetic agent 5	Amylases Glucosidase	Metabolic Disease
Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and *α-amylase* with IC₅₀ values of 3.91, 8.89 µM, respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .

HY-Y0598

trans-Chalcone	Fatty Acid Synthase (FASN) Apoptosis Fungal	Inflammation/Immunology Cancer
trans-Chalcone, isolated from Aronia melanocarpa skin, is a biphenolic core structure of flavonoids precursor. trans-Chalcone is a potent fatty acid synthase (FAS) and *α-amylase* inhibitor. trans-Chalcone causes cellcycle arrest and induces apoptosis in the breastcancer cell line MCF-7. trans-Chalcone has antifungal and anticancer activity .

HY-155961

Antidiabetic agent 2	Dipeptidyl Peptidase Phosphatase Amylases Glucosidase	Metabolic Disease
Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, *α-amylase, and α-glucosidase* with IC₅₀s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .

HY-N12688

2,3-Dihydrocalodenin B	Glucosidase Amylases	Metabolic Disease
2,3-Dihydrocalodenin B (Compound 6) is a compound that can be isolated from Knema globularia. 2,3-Dihydrocalodenin B is a potent and non-competitive inhibitor against α-glucosidase and *α-amylase, with IC₅₀* values of 1.1 and 2.6 μM, respectively. 2,3-Dihydrocalodenin B can be used for the research of diabetes .

HY-161469

α-Amylase/α-Glucosidase-IN-13	Amylases Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-13 (Compound 5d) is a dual inhibitor of *α-Amylase/α-Glucosidase* that can be used for diabetes research .

HY-154972

α-Amylase/α-Glucosidase-IN-3	Glucosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an *α-Amylase/α-Glucosidase* dual inhibitor, with IC₅₀s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .

HY-126052

Gnetol	COX Tyrosinase HDAC	Metabolic Disease Cancer
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC₅₀ of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC₅₀ of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .

HY-159491

DPP-4-IN-11	Dipeptidyl Peptidase Glucosidase Amylases	Metabolic Disease
DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC₅₀=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC₅₀=3.02 μM) and *α-amylase* (IC₅₀=3.3 μM) .

HY-W068682

1-Hydroxyphenazine Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin	Amylases Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
1-Hydroxyphenazine (Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin) is an inhibitor for *α-Amylase* with an IC₅₀ of 3.1 μg/mL . 1-Hydroxyphenazine exhibits anticancer and anti-inflammatory activity against cells A549, 1321N1 and RAW264.7, antifungal and antibacterial activity against strains Candida albicans, Aspergillus fumigatus, Escherichia coli and Xanthomonas campestris .

HY-168074

4″-C18 EGCG	Amylases Glucosidase	Metabolic Disease Inflammation/Immunology
4″-C18 EGCG is a potent inhibitor of *α-amylase* and α-glucosidase with IC₅₀ values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM .

HY-161764

α-Glucosidase-IN-67	Amylases Glucosidase	Metabolic Disease
α-Glucosidase-IN-67 (compound 5k) is a potent α-Glucosidase inhibitor with IC₅₀ values of 0.31, 4.51 µM for alpha-glucosidase and alpha-amylase, respectively. α-Glucosidase-IN-67 has the potential for the research of type-2 diabetes .

HY-N12650

Kaempferol 3-O-alpha-L-(2, 3-di-Z-p-coumaroyl) rhamnoside	Endogenous Metabolite	Metabolic Disease
Kaempferol 3-O-alpha-L-(2, 3-di-Z-p-coumaroyl) rhamnoside (compound 42) is a flavonol that can be isolated from Platanus Occidentalis. Kaempferol 3-O-alpha-L-(2, 3-di-Z-p-coumaroyl) rhamnoside is an inhibitor of alpha-amylase and DPP IV .

HY-N11728

2,7"-Phloroglucinol-6,6'-bieckol	Amylases Glucosidase	Metabolic Disease
2,7"-Phloroglucinol-6,6'-bieckol is an orally active dual *α-amylase/α-glucosidase* inhibitor with IC₅₀ values of 6.94 μM and 23.35 μM respectively. 2,7"-Phloroglucinol-6, 6'-bieckol alleviates postprandial hyperglycemia in diabetic mice. 2,7"-Phloroglucinol-6,6'-bieckol can be used in diabetes research .

Cat. No.	Product Name	Target	Research Area

HY-P2055

A-57696	Peptides	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

α-Amylase Inhibitor

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Natural
Products